TIGIT Inhibitors Clinical Trial Pipeline Appears Robust with 18+ Key Pharma Players Actively Working in the Space, Estimates DelveInsight

News provided by

Nov 16, 2022, 10:30 ET

TIGIT Inhibitors clinical trial pipeline constitutes 18+ key companies continuously working towards developing 20+ TIGIT inhibitors drugs, analyzes DelveInsight

LAS VEGAS, Nov. 16, 2022 /PRNewswire/ -- DelveInsight's 'TIGIT Inhibitors Competitive Landscape – 2022' report provides comprehensive global coverage of available, marketed, and pipeline TIGIT inhibitor drugs in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the TIGIT inhibitors competitive domain.

Key Takeaways from the TIGIT Inhibitors Pipeline Report

Over 18+ TIGIT inhibitors companies are evaluating 20+ TIGIT inhibitors pipeline therapies in various stages of development, and their anticipated acceptance in the TIGIT inhibitors market would significantly increase market revenue.
Leading TIGIT inhibitor companies such as Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, and others are evaluating novel TIGIT inhibitor drugs candidate to improve the treatment landscape.
Key TIGIT inhibitor pipeline therapies in various stages of development include Vibostolimab, BMS 986442, Ociperlimab, Domvanalimab, EOS 448, Etigilimab, PH 804-TME, PH 804-ACT, BAT6005, Vibostolimab, M 6223, COM 902, BMS 986442, and others.
On September 13, 2022, Akeso, Inc., a China-based biopharmaceutical company focused on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, presented encouraging preclinical results in a poster featuring its Fc-mutant anti-TIGIT antibody fused with TGF-RII protein (AK130) at the European Society for Medical Oncology (ESMO) Congress 2022.
On May 13, 2022, iTeos Therapeutics stated that it is evaluating whether to conduct additional clinical trials of TIGIT drug EOS-448 with partner GlaxoSmithKline following the failure of a key trial for Roche's rival drug.
In December 2021, Bio-Thera Solutions, a commercial-stage pharmaceutical company, announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics and safety of BAT6005, a monoclonal antibody targeting TIGIT in cancer patient volunteers.
In June 2021, GlaxoSmithKline and iTeos Therapeutics announced an agreement to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer. TIGIT, part of the CD226 checkpoint axis, has demonstrated potential as a promising target for the next generation of immuno-oncology therapies based on compelling preclinical data and a phase II randomized clinical trial.

Request a sample and discover the recent advances in the TIGIT inhibitors market @TIGIT Inhibitors Competitive Landscape Report

TIGIT Inhibitors Overview

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is one of the most recently investigated immune checkpoints as an immunotherapeutic target. TIGIT is a transmembrane glycoprotein receptor with an Ig-like V-type domain in its cytoplasmic domain and an ITIM in its extracellular domain. It is found on activated and memory T cells, as well as NK cells and Tregs. Binding to either of its two APC ligands, CD155 (PVR: poliovirus receptor) or CD112 (PVRL2, nectin-2), inhibits maturation and confers a tolerogenic phenotype.

TIGIT-blockade clinical trials in cancer have recently begun in large numbers, mostly as combination treatments. TIGIT-Fc fusion protein has been shown to interact with PVR on dendritic cells, increase IL-10 secretion/decrease IL-12 secretion in response to LPS stimulation, and inhibit T cell activation in vivo. Antibodies against TIGIT's interaction with PVR can block its inhibition of NK cytotoxicity, and the activity is directed through its ITIM domain.

Find out more about FDA TIGIT inhibitors @TIGIT Inhibitor Drugs List

TIGIT Inhibitors Pipeline Analysis: Drug Profile

Ociperlimab: BeiGene

BeiGene's Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody with high specificity and affinity for TIGIT. Ociperlimab is a cutting-edge, developing anti-TIGIT antibody with an intact IgG Fc binding region for optimal antibody-mediated anti-tumor activity. Ociperlimab binds to TIGIT and prevents it from interacting with poliovirus receptor (CD155) and poliovirus receptor-related 2 (CD112) ligands on tumor cells, activating T cell-mediated antitumor immune responses.

BAT6005: Bio-Thera Solutions

BAT6005, developed by Bio-Thera Solutions, is a monoclonal antibody that targets TIGIT in cancer patient volunteers. BAT6005 was discovered using Bio-Thera's proprietary IDEAL (Intelligent Design and Engineered Antibody Libraries) platform, and it has normal IgG1 ADCC function.

A snapshot of the TIGIT Inhibitors Pipeline Drugs mentioned in the report:

TIGIT Inhibitors Drugs	Company	Phase	Indication
Ociperlimab	BeiGene	Phase III	NSCLC
MK-7684A (pembrolizumab/vibostolimab)	Merck Sharp & Dohme	Phase III	Non-Small-Cell Lung Carcinoma
Domvanalimab + Zimberelimab	Arcus Biosciences	Phase III	NSCLC
BMS 986207	Bristol-Myers Squibb	Phase II	NSCLC
AGEN 1777 + PD-1 Inhibitor	Agenus	Phase I	Advanced Solid Tumors
BAT6005	Bio-Thera Solutions	Phase I	Locally Advanced or Metastatic Solid Tumors
PH 804	Phio Pharmaceuticals	Preclinical	Solid tumors
TSRF-786-C	Tasrif Pharmaceutical	Preclinical	Cancer

Learn more about the TIGIT inhibitor drugs @TIGIT Inhibitor Trials

Scope of the TIGIT Inhibitors Competitive Landscape Report

Coverage: Global
Key TIGIT Inhibitors Companies: Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, and others
Key TIGIT Inhibitors Pipeline Therapies: Vibostolimab, BMS 986442, Ociperlimab, Domvanalimab, EOS 448, Etigilimab, PH 804-TME, PH 804-ACT, BAT6005, Vibostolimab, M 6223, COM 902, BMS 986442, and others.

Dive deep for rich insights into TIGIT inhibitor therapy; visit @FDA-approved TIGIT Inhibitors

Table of Contents

1.	TIGIT Inhibitors Pipeline Report Introduction
2.	TIGIT Inhibitors Pipeline Report Executive Summary
3.	TIGIT Inhibitors Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	TIGIT Inhibitors Clinical Trial Therapeutics
6.	TIGIT Inhibitors Pipeline: Late Stage Products (Pre-registration)
7.	TIGIT Inhibitors Pipeline: Late Stage Products (Phase III)
8.	TIGIT Inhibitors Pipeline: Mid Stage Products (Phase II)
9.	TIGIT Inhibitors Pipeline: Early Stage Products (Phase I)
10.	TIGIT Inhibitors Pipeline Therapeutic Assessment
11.	Inactive Products in the TIGIT Inhibitors Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the TIGIT Inhibitors Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the TIGIT inhibitors therapeutics assessment, reach out @TIGIT Inhibitor Therapy

Non-Small Cell Lung Cancer Market Insights, Epidemiology and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology current treatment practices, emerging drugs, and key non-small cell lung cancer companies, including Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company, Sanofi, Pfizer, and others.

Non-Small Cell Lung Cancer Epidemiology Forecast

Non-Small Cell Lung Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted non-small cell lung cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Small-cell Lung Cancer Pipeline

Small-cell Lung Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key small-cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, among others.

Small-cell Lung Cancer Market

Small-cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key small-cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, among others.

Extensive Stage Small Cell Lung Cancer Pipeline

Extensive Stage Small Cell Lung Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key extensive stage small cell lung cancer companies, including Eli Lilly and Company, Genentech, Bristol-Myers Squibb, Henlix Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Haihe Biopharma Co., Ltd., Taizhou HoudeAoke Biomedical Co., Ltd, Celgene, among others.

Other Trending Reports